Acquiring Company
Gland Pharma Limited
Acquired Company
Novelstar Pharma
Hyderabad
United StatesBiotechnologyPharmaceuticalBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Gland Pharma has announced an investment of up to $21 million in its subsidiary, Gland Pharma USA Inc., to acquire a 60% stake in Novelstar Pharma Inc. This strategic move aims to expand Gland Pharma's portfolio and market presence in the biopharmaceutical sector. Following this acquisition, Novelstar Pharma will operate as a step-down subsidiary of Gland Pharma, with Fosun Pharma USA Inc. retaining the remaining 40% stake.
Fundz sees it the moment Gland Pharma Limited makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Novelstar Pharma?
Novelstar Pharma was acquired by Gland Pharma Limited, based in Hyderabad. The deal was reported on October 5, 2026. Gland Pharma Limited is a pharmaceutical company with a global presence, specializing in API operations & development, global supply planning & operations, and corporate strategic business planning. Gland Pharma Limited is privately held and operates in Biotechnology.
When did Gland Pharma Limited acquire Novelstar Pharma?
Gland Pharma Limited's acquisition of Novelstar Pharma was reported on October 5, 2026. Gland Pharma has announced an investment of up to $21 million in its subsidiary, Gland Pharma USA Inc., to acquire a 60% stake in Novelstar Pharma Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Novelstar Pharma do?
Novelstar Pharma Inc. is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs. The company is engaged in the research and development of advanced drug formulations for various therapeutic areas. It is privately held, operating in Biotechnology, and is based in United States.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.